Compare Amgen, Inc. (AMGN) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Kinross Gold Corporation — how do they compare? Amgen, Inc. trades at $357 (market cap $196.12B), while Kinross Gold Corporation trades at $23.78 (market cap $28.72B). The key difference: Amgen, Inc. is far larger — about 6.8× Kinross Gold Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | KGC | |
|---|---|---|
Market Cap | $196.12B | $28.72B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $38.06 |
52-Week Low | $271.18 | $15.33 |
Enterprise Value | $241.41B | $27.28B |
Dividend Yield | 2.77% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KGC trades at $24.14, down 0.25% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals, with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Valuation ratios are attractive, including a P/E of 10.27 and EV/EBITDA of 5.3. Recent earnings have consistently beaten expectations, and a dividend of $0.04 per share was declared for H1-26.
The outlook is positive due to robust cash flow growth, a healthy balance sheet, and analyst consensus favoring a buy rating with a $36.25 price target. Key risks include potential margin pressure from rising costs and broader market volatility affecting gold prices. The stock presents a value opportunity if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
